16:06:05 Europe / Stockholm


2023-11-13 08:23:00

Redeye comments on Cantargia's third quarter report. In the next twelve months, the most obvious value drivers of the share are the phase II study in breast cancer (TRIFOUR) and the first clinical study of CAN10 intended for inflammatory diseases.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/